Biotech startup Korsana Biosciences raises $175 million to advance Alzheimer's disease antibody therapy.[1] Investors believe there is room in the market for additional Alzheimer's antibody therapies. This funded development supports research into new antibody treatment options. The article highlights the potential to expand available therapies in this area.